Equities Analysts Issue Forecasts for BHST Q1 Earnings

Key Points

• HC Wainwright forecasts Q1 2026 EPS of ($0.04) and a FY2026 loss of ($0.22), well above the consensus loss of ($0.80), providing quarter-level guidance that suggests a smaller near-term loss and reduced financing concerns.
• The firm also cut long‑term estimates—FY2027 from $0.22 to $0.07, FY2028 from $0.55 to $0.37, and FY2029 from $1.00 to $0.80—which lowers the company’s projected growth trajectory and valuation assumptions.
• BHST is trading around $4.30 with a market cap of about $84M; analyst coverage is mixed (two Buys, one Sell) with a consensus rating of "Hold" and an average price target of $12.50, while several institutions have recently established small positions.

BioHarvest Sciences Inc. (NASDAQ:BHST - Free Report) - Equities researchers at HC Wainwright issued their Q1 2026 earnings estimates for BioHarvest Sciences in a research report issued to clients and investors on Tuesday, April 14th. HC Wainwright analyst A. Dayal forecasts that the company will post earnings of ($0.04) per share for the quarter. The consensus estimate for BioHarvest Sciences' current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for BioHarvest Sciences' Q2 2026 earnings at ($0.09) EPS, Q3 2026 earnings at ($0.05) EPS, Q4 2026 earnings at ($0.04) EPS, FY2026 earnings at ($0.22) EPS, FY2027 earnings at $0.07 EPS and FY2028 earnings at $0.37 EPS.

Other research analysts also recently issued research reports about the stock. Roth Mkm started coverage on shares of BioHarvest Sciences in a research report on Thursday, February 19th. They set a "buy" rating and a $10.00 price objective on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of BioHarvest Sciences in a research report on Friday, March 27th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $12.50.

BioHarvest Sciences Stock Up 0.7%

Shares of BioHarvest Sciences stock opened at $4.30 on Thursday. The company has a market cap of $84.35 million, a price-to-earnings ratio of -7.05 and a beta of 1.16. The company's 50 day moving average is $4.44 and its 200 day moving average is $6.24. BioHarvest Sciences has a twelve month low of $4.10 and a twelve month high of $12.80. The company has a quick ratio of 3.38, a current ratio of 3.97 and a debt-to-equity ratio of 0.10.

Hedge Funds Weigh In On BioHarvest Sciences

Several institutional investors have recently made changes to their positions in BHST. Virtu Financial LLC bought a new position in shares of BioHarvest Sciences in the 4th quarter worth approximately $60,000. Geode Capital Management LLC bought a new position in shares of BioHarvest Sciences in the 4th quarter worth approximately $61,000. HRT Financial LP bought a new position in shares of BioHarvest Sciences in the 4th quarter worth approximately $75,000. Marshall Wace LLP bought a new position in shares of BioHarvest Sciences in the 4th quarter worth approximately $110,000. Finally, Quadrature Capital Ltd bought a new position in shares of BioHarvest Sciences in the 4th quarter worth approximately $140,000.

Key Headlines Impacting BioHarvest Sciences

Here are the key news stories impacting BioHarvest Sciences this week:

• Positive Sentiment: HC Wainwright now models a FY2026 loss of ($0.22) and quarter-by-quarter 2026 EPS of ($0.04), ($0.09), ($0.05) and ($0.04). Those FY2026 figures imply a much smaller loss than the consensus (-$0.80), which reduces near-term financing and path‑to‑profit concerns. MarketBeat Report
• Neutral Sentiment: The note gives detailed quarter-level guidance for 2026 and projects positive earnings in later years (FY2027 and beyond in HC Wainwright’s model), providing clearer visibility on the firm’s expected cadence to profitability — useful but not a guaranteed outcome. MarketBeat Report
• Negative Sentiment: HC Wainwright cut long‑term estimates: FY2027 from $0.22 to $0.07, FY2028 from $0.55 to $0.37 and FY2029 from $1.00 to $0.80. Those downgrades reduce the company’s growth trajectory and likely lower valuation assumptions, which is the main negative driver for today’s pullback. MarketBeat Report

About BioHarvest Sciences

BioHarvest Sciences Inc is a biotechnology company that specializes in the development and commercialization of plant-based active ingredients through proprietary cell-culture technology. By growing undifferentiated plant cells in controlled bioreactor environments, the company aims to produce full-spectrum phytonutrients and botanical compounds that are difficult to obtain through traditional farming methods. This approach is designed to deliver consistent, high-purity extracts with reduced environmental impact and supply-chain variability.

The company's product portfolio focuses on applications across the cosmeceutical, nutraceutical and health-and-wellness markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.